Gyros AB licenses patented technology to Fluidigm Corporation
Gyros AB and Fluidigm Corporation today announced finalization of a licensing agreement of a patent family held by Gyros which covers certain microfluidic devices based on elastomeric layers. The Gyros patent applies in the US and in additional major biotech markets worldwide.
Maris Hartmanis, President and CEO at Gyros AB explained, "We are very pleased that Fluidigm has agreed to become the initial licensee of one of Gyros' early patent filings. We expect that additional companies will also sign up for our licensing program."
Gajus Worthington, President and CEO of Fluidigm added, "this is great technology, and Fluidigm is delighted to have access to it."
Fluidigm has successfully commercialized the Topaz(TM) Crystallizer to automate the metering, mixing, and isolation of protein crystallization experiments. This system is enabled by a proprietary process known as Multi-layer Soft Lithography (MSL(TM)) to manufacture three-dimensional structures from multiple layers of soft elastomer. With this technology, Fluidigm intends to provide an increasing range of products for the biotechnology research market.
Hartmanis continued, "Gyros and Fluidigm are at the forefront in the development of their respective microfluidic technologies. It will be a fascinating journey as we produce more application solutions and see microfluidic-based technologies become standard in the world of drug discovery."
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Chemicals in the environment: A focus on mixtures - Combined chemical and bioanalytical methods are able to efficiently characterise chemical mixtures
Black sheep: Why some strains of the Epstein Barr virus cause cancer

New tool analyzes disease and drug effects with unprecedented accuracy and consistency
U.S. Genomics Licenses Locked Nucleic Acid (LNA(TM)) Chemistries from Exiqon - LNA(TM) chemistries included in Trilogy(TM) platform reagent kits for microRNA analysis

A molecular switch for the X chromosome - Elucidation of basic mechanism to initiate the inactivation of X chromosomes in female organisms
Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
